Loxoribine
- CAS No.
- 121288-39-9
- Chemical Name:
- Loxoribine
- Synonyms
- RWJ 21757;Loxoribine;7,8-Dihydro-8-oxo-7-allyl-guanosine;7-Allyl-7,8-dihydro-8-oxoguanosine 95%;7-ALLYL-7 8-DIHYDRO-8-OXOGUANOSINE 95;7,8-Dihydro-8-oxo-7-(2-propenyl)guanosine;Guanosine, 7,8-dihydro-8-oxo-7-(2-propenyl)-;7,8-dihydro-8-oxo-7-allyl-guanosine, Loxoribine;Guanosine, 7,8-dihydro-8-oxo-7-(2-propen-1-yl)-;7-Allyl-7,8-dihydro-8-oxoguanosine (Loxoribine)
- CBNumber:
- CB7499469
- Molecular Formula:
- C13H17N5O6
- Molecular Weight:
- 339.3
- MDL Number:
- MFCD00867591
- MOL File:
- 121288-39-9.mol
| Melting point | 227-230 °C(lit.) |
|---|---|
| Density | 1.92±0.1 g/cm3(Predicted) |
| storage temp. | Desiccate at +4°C |
| solubility | Soluble in DMSO (up to 25 mg/ml). |
| pka | 10.29±0.20(Predicted) |
| form | White to off-white solid. |
| color | White |
| optical activity | [α]21/D 32°, c = 1 in H2O |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
| FDA UNII | 9CAS0V66OI |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
| WGK Germany | 3 |
| HS Code | 29349990 |
Loxoribine price More Price(19)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | 496812 | 7-Allyl-7,8-dihydro-8-oxoguanosine 95% | 121288-39-9 | 50mg | $82.4 | 2024-03-01 | Buy |
| Sigma-Aldrich | 496812 | 7-Allyl-7,8-dihydro-8-oxoguanosine 95% | 121288-39-9 | 250mg | $192.4 | 2024-03-01 | Buy |
| Cayman Chemical | 21186 | Loxoribine ≥98% | 121288-39-9 | 5mg | $32 | 2024-03-01 | Buy |
| Cayman Chemical | 21186 | Loxoribine ≥98% | 121288-39-9 | 10mg | $61 | 2024-03-01 | Buy |
| Cayman Chemical | 21186 | Loxoribine ≥98% | 121288-39-9 | 25mg | $86 | 2024-03-01 | Buy |
Loxoribine Chemical Properties,Uses,Production
Description
Loxoribine is a guanosine derivative and an agonist of toll-like receptor 7 (TLR7). It is selective for TLR7 over other human TLRs in a cell-based reporter assay at 1 mM.. Loxoribine induces proliferation, increases the antibody response to sheep red blood cells, and activates natural killer cell activity against Yac-1 lymphoma cells in murine splenocyte cultures (EC50s = 10-50, 3-20, and 13-22 μM, respectively). Loxoribine (250 μM) increases production of IL-12, IL-23, IL-27, and IL-10 by human monocyte-derived dendritic cells (MoDCs). Loxoribine-treated MoDCs induce higher levels of IL-17 and IFN-γ secretion by co-cultured allogeneic CD4+ T cells compared to control MoDCs. Loxoribine (120 mg/kg) reduces the number of pulmonary metastases in the B16 mouse model of melanoma, an effect enhanced by co-administration of IL-2, and exhibits adjuvant activity in mice immunized with a B16 tumor vaccine.
Chemical Properties
White Solid
Uses
Small-molecule immunostimulants
Uses
Loxoribine is a selective toll-like receptor 7 (TLR7) agonist that activates immune cells and increases cytokine production.
Uses
7-Allyl-7,8-dihydro-8-oxoguanosine (Loxoribine) is a small-molecule immunostimulant. Loxoribine is a toll-like receptor 7 (TLR7) agonist; induces immune cell activation and increases cytokine product ion. Loxoribine displays antitumor and antiviral activity in various animal models.
Biological Activity
Toll-like receptor 7 (TLR7) agonist; induces immune cell activation and increases cytokine production. Displays antitumor and antiviral activity in various animal models.
References
1) Heil?et al.?(2003),?The Tool-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily; Eur. J. Immunol.,?33?2987 2) Goodman?et al.?(1995),?A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine;?Pharm. Biotechnol.,?6?581 3) Girart?et al.?(2007), Engagement of TLR3, TLR7 and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12; J. Immunol.,?179?3472 4) Stewart?et al.?(2012),?Toll-like receptor 7 ligands inhibit influenza A infection in chickens; J. Interferon Cytokine Res,,?32?46 5) Wang?et al.?(2015),?The TLR7 agonist induces tumor regression both by promoting CD4-T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells; Oncotarget,?6?1779
Loxoribine Preparation Products And Raw materials
Raw materials
Preparation Products
Loxoribine Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Hubei xin bonus chemical co. LTD | 86-13657291602 | linda@hubeijusheng.com | CHINA | 22963 | 58 |
| SHANGHAI T&W PHARMACEUTICAL CO., LTD. | +86-021-61551413 +8618813727289 | contact@trustwe.com | China | 5738 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32161 | 58 |
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | laboratory@coreychem.com | China | 30238 | 58 |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | 1026@dideu.com | China | 22785 | 58 |
| BOC Sciences | 16314854226; +16314854226 | inquiry@bocsci.com | United States | 19741 | 58 |
| NewCan Biotech Limited | +86-0571-86912261 +8613735419629 | sales@newcanbio.com | China | 9981 | 58 |
| LEAPCHEM CO., LTD. | +86-852-30606658 | market18@leapchem.com | China | 43340 | 58 |
| Shanghai Acmec Biochemical Technology Co., Ltd. | +undefined18621343501 | product@acmec-e.com | China | 33338 | 58 |
| SHANGHAI KEAN TECHNOLOGY CO., LTD. | +8613817748580 | cooperation@kean-chem.com | China | 40066 | 58 |
View Lastest Price from Loxoribine manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-11-18 | Loxoribine
121288-39-9
|
US $31.00-84.00 / mg | 99.73% | 10g | TargetMol Chemicals Inc. |
-
- Loxoribine
121288-39-9
- US $31.00-84.00 / mg
- 99.73%
- TargetMol Chemicals Inc.